7 fast-acting sublingual therapies entering clinical practice in 2026
As 2026 begins, global urological associations are updating clinical guidelines to incorporate next-generation sublingual phosphodiesterase-5 inhibitors that bypass traditional gastrointestinal metabolism. These regulatory updates from the FDA and European Medicines Agency focus on reducing the onset time of medication while...
English
Arabic
French
Spanish
Portuguese
Deutsch
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek